Product category:
Proteomics
News Release from: Pronota | Subject: Massterclass
Edited by the Laboratorytalk Editorial
Team on 31 March 2008
Novel platform for protein biomarker
verification
The Massterclass platform addresses a key bottleneck in biomarker development by enabling large-scale screening of biomarker candidates without the requirement to raise antibodies
Pronota, a Belgium-based biomarker discovery and development company, announced today the launch of Massterclass, its highly-sensitive protein biomarker verification tool, at the Molecular Medicine Tri-Conference in San Francisco The system raises the analytical bar for antibody-free protein assays by quantitating in the low nanogram per ml concentration range in blood plasma, thereby enabling efficient and reliable measurement of proteins specific to disease or drug response, says the company
This article was originally published on Laboratorytalk on 6 Nov 2002 at 8.00am (UK)
Related stories
Haematology analyser fills gap in range
With a throughput of 80 samples per hour, this will suit laboratories with workloads of up to 350 samples per day and fills the gap between 60 and 120 sample per hour machines
Innovative new products emphasise R and D
Completely new bench-top analyser combines the latest technological advances and a large test menu with a faster throughput
Massterclass incorporates a novel series of orthogonal complexity reduction steps combined with targeted tandem mass spectrometry to achieve required sensitivity levels while maintaining analytical reproducibility.
The workflow also ensures that throughput is maintained when screening large panels of biomarker candidates by multiplexing different analytes in the same assay.
The new platform complements Masstermind, Pronota's biomarker discovery platform capable of generating a high quality hit-list of low-abundance protein biomarkers in blood.
The combination of both platforms represents an integrated approach that significantly increases the chances of taking a biomarker from discovery through to clinical implementation within a practical timeframe.
"The introduction of Massterclass represents an important milestone for Pronota", commented Nick McCooke, CEO.
"The platform allows Pronota and our partners to bridge the gap between biomarker discovery and the final clinical assay through the efficient assessment and selection of the most promising candidates with the best clinical performance either alone or combined in panels".
• Pronota: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
